<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158082">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01898793</url>
  </required_header>
  <id_info>
    <org_study_id>201401085</org_study_id>
    <nct_id>NCT01898793</nct_id>
  </id_info>
  <brief_title>Cytokine-induced Memory-like NK Cells in Patients With Relapsed and Refractory AML</brief_title>
  <acronym>NK</acronym>
  <official_title>A Phase 1 Study of Cytokine-induced Memory-like NK Cells in Patients With Relapsed and Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of activated natural killer cells
      in treating patients with relapsed or refractory acute myeloid leukemia.  Giving
      chemotherapy before a donor natural killer cell infusion helps stop the growth of cancer
      cells.  It may also stop the patient's immune system from rejecting the donor's natural
      killer cells.  Modified natural killer cells may help the body build an immune response to
      kill cancer cells.  Aldesleukin (interleukin-2) may stimulate the white blood cells
      (including natural killer cells) to kill leukemia cells.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MTD of CIML-NK cells in relapsed or refractory AML patients</measure>
    <time_frame>35 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity (DLT) or the maximum dose if less than or equal to 1 patient suffers a DLT at the maximum dose. Summary statistics including proportions and their 95% confidence interval will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response assessed according to IWG criteria</measure>
    <time_frame>35 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reported with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR is defined only for patients who achieve a CR or PR, and is measured from the first  date of attaining CR or PR until the date of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>TTP is defined as the time from date of first dose of fludarabine until evidence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DFS is defined as the time from the day  CR or CRi is documented until disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS is defined from the date of first dose of fludarabine on this study until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by the frequency and incidence of serious adverse events</measure>
    <time_frame>Up to 100 days after conclusion of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Graded using the National Cancer (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.  Summary statistics including proportions and their 95% confidence interval will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYMPHODEPLETING PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
DONOR LEUKAPHERESIS: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
CIML NK CELLS: Patents undergo CIML NK cell infusion over 15-60 minutes on day 0.
Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYMPHODEPLETING PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
DONOR LEUKAPHERESIS: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
CIML NK CELLS: Patents undergo CIML NK cell infusion over 15-60 minutes on day 0.
Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYMPHODEPLETING PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
DONOR LEUKAPHERESIS: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
CIML NK CELLS: Patents undergo CIML NK cell infusion over 15-60 minutes on day 0.
Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>75607-67-9</other_name>
    <other_name>9H-purin-6-amine</other_name>
    <other_name>2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>fludarabine-5'-monophosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
    <other_name>CytoxanÂ®</other_name>
    <other_name>CPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytokine-induced killer cells</intervention_name>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
    <other_name>CIK cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <arm_group_label>Level 1:  0.5 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 2: 1.0 x 106/kg CIML NK cells</arm_group_label>
    <arm_group_label>Level 3: All CIML NK cells available from donor leukapheresis</arm_group_label>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
    <other_name>Ro-236019</other_name>
    <other_name>T-cell growth factor</other_name>
    <other_name>TCGF</other_name>
    <other_name>TCGF,</other_name>
    <other_name>interleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory AML without complete remission (CR) after induction therapy (primary
             induction failure) or relapsed AML after obtaining a CR.

          -  At least 18 years of age.

          -  Available HLA-haploidentical donor that meets the following criteria:

               -  Related donor (sibling, offspring, or offspring of sibling)

               -  At least 18 years of age

               -  HLA-haploidentical donor/recipient match by at least Class I serologic typing at
                  the A&amp;B locus.

               -  In general good health, and medically able to tolerate leukapheresis required
                  for harvesting the NK cells for this study.

               -  Negative for hepatitis, HTLV, and HIV on donor viral screen

               -  Not pregnant

               -  Voluntary written consent to participate in this study

          -  Patients with known CNS involvement with AML are eligible provided that they have
             been treated and CSF is clear for at least 2 weeks prior to enrollment into the
             study. CNS therapy (chemotherapy or radiation) should continue as medically indicated
             during the study treatment.

          -  Karnofsky performance status â¥ 50 %

          -  Adequate organ function as defined below:

               -  Total bilirubin â¤ 2 mg/dl

               -  AST(SGOT)/ALT(SGPT) â¤ 3.0 x IULN

               -  Creatinine within normal institutional limits OR creatinine clearance â¥ 50
                  mL/min/1.73 m2 by Cockcroft-Gault Formula

               -  Oxygen saturation â¥90% on room air

               -  Ejection fraction â¥35%

          -  Able to be off of corticosteroids and any other immune suppressive medications
             beginning on Day -3 and continuing until 30 days after the infusion of the CIML NK
             cells.

          -  Women of childbearing potential must have a negative pregnancy test within 28 days
             prior to study registration. Female and male patients (along with their female
             partners) must agree to use two forms of acceptable contraception, including one
             barrier method, during participation in the study and throughout the DLT evaluation
             period.

          -  Ability to understand and willingness to sign an IRB approved written informed
             consent document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Relapsed after allogeneic transplantation.

          -  Circulating blast count â¥30,000/dL by morphology or flow cytometry (cytoreductive
             therapies including leukapheresis or hydroxyurea are allowed).

          -  Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.

          -  Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive
             of acute ischemia or active conduction system abnormalities.

          -  New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that
             have not been evaluated with bronchoscopy. Infiltrates attributed to infection must
             be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or
             proven fungal infections).

          -  Known hypersensitivity to one or more of the study agents.

          -  Received any investigational drugs within the 14 days prior to the first dose of
             fludarabine.

          -  Pregnant and/or breastfeeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rizwan Romee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rizwan Romee, M.D.</last_name>
    <phone>314-747-1385</phone>
    <email>rromee@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rizwan Romee, M.D.</last_name>
      <phone>314-747-1385</phone>
      <email>rromee@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meagan Jacoby, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Schroeder, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Stockerl-Goldstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Uy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Vij, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Wartman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Welch, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Westervelt, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1915-9. doi: 10.1073/pnas.0813192106. Epub 2009 Jan 30.</citation>
    <PMID>19181844</PMID>
  </reference>
  <reference>
    <citation>Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA. Cytokine activation induces human memory-like NK cells. Blood. 2012 Dec 6;120(24):4751-60. doi: 10.1182/blood-2012-04-419283. Epub 2012 Sep 14.</citation>
    <PMID>22983442</PMID>
  </reference>
  <reference>
    <citation>Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med. 2012 Dec 17;209(13):2351-65. doi: 10.1084/jem.20120944. Epub 2012 Dec 3.</citation>
    <PMID>23209317</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine monophosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
